leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024

Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024

Opportunities for Leading Companies

Product code: PHA0004

  • Publication date: 15/08/2014
  • Number of Pages: 182
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

Alzheimer’s medicine – your guide to technologies, trends and revenues
Where is the Alzheimer’s disease treatment market heading? Visiongain’s new report gives you revenue predictions for those drugs and diagnostic tests from 2014, helping you stay ahead.

Our 182-page report provides 131 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Dr. Simon Ridley, Head of Research, Alzheimer’s Research UK
- David Hanlon, Director of Business Development and Strategic Collaborations, Quanterix
- Elizabeth Edgerly, PhD., Chief Program Officer, The Alzheimer’s Association Northern California and Northern Nevada

Many opportunities exist for diagnosis and treatment of Alzheimer’s. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead

Discover sales predictions for the world market and submarkets
Along with revenue prediction of the overall world market, you see forecasts to 2024 for these two submarkets:
• Medicines for Alzheimer’s disease
• Diagnostics for Alzheimer’s (including biomarkers).

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for Alzheimer’s disease drugs
How will leading drugs perform to 2024 at world level? Our study predicts individual revenues of three products:
• Namenda
• Aricept
• Exelon

And also three pipeline products:
• Solanezumab
• Gantenerumab
• MK-8931

There you discover how high sales can go. You see what’s happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2014.

In addition to analyses of the overall world market, you discover revenue forecasts for 11 leading national markets to 2024:
• US
• Japan
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• China
• Brazil
• Russia
• India
• Rest of the World

There you find potential. Large companies and specialty biopharma and diagnostics firms face many opportunities. Our study explains, assessing developments to help your work.

Leading companies and potential for market growth
Overall world revenue for Alzheimer’s disease therapeutics and diagnostics will reach $7.0bn in 2014, our work forecasts. Our new study predicts the market will expand fast, especially beyond 2018. Disease-modifying therapies will transform that market. New drugs hold great potential from 2018 to 2024, given the prevalence of Alzheimer’s and needs for more-effective treatments.

Our work shows you what organisation hold greatest potential. See profiles of 14 leading companies, including these:
• Pfizer
• Eisai
• Forest Laboratories
• Lundbeck
• Daiichi Sankyo
• Novartis
• TauRx Therapeutics
• Transtech Pharma
• Eli Lilly
• Amarantus BioScience Holdings, Inc
• Piramal Enterprises
• GE Healthcare
• Navidea
• Diagenic

In general, a company profile gives you the following information:
• Revenue forecasts for Alzheimer’s disease drugs from 2014 to 2024
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What affects producers of those diagnostic tests and medicines?
Our report discusses issues and events affecting that industry and market from 2014, including these:
• Research and development (R&D) – drugs, diagnostic tests, and related technologies
• Disease prevalence – expanding patient populations
• Disease-modifying drugs and obstacles to cures
• Regulatory guidelines – changes and opportunities.

The study also discusses other aspects of diagnosing and treating Alzheimer’s:
• Needs for Alzheimer’s treatments
• Drugs and related technologies to transform the market
• Biomarkers and diagnostic imaging technologies, including structural, functional, and molecular imaging
• Diagnostic tests in development
• Deep brain stimulation (functional neuromodulation)
• Intellectual property (IP), licensing agreements and partnerships.

That way, you explore the industry’s strengths, weaknesses, opportunities, and threats. You also analyse it through Porter’s five forces.

See, then, what the future holds.

How the Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024: Opportunities for Leading Companies report helps you
In summary, our 182-page report gives you the following knowledge:
Revenue forecast to 2024 for the world Alzheimer’s disease therapeutics and diagnostics market and 2 submarkets - Discover the industry’s prospects, finding promising places for investment and revenues.
Revenue forecasts to 2024 for the leading 11 national markets – US, Japan, Germany, France, UK, Italy, Spain, Rest of Europe, Brazil, Russia, China, India, and Rest of the World
Assessment of 14 leading companies – hear about products, results and strategies including revenue forecasts for Alzheimer’s disease drugs to 2024
Predicted revenues for 3 Alzheimer’s disease drugs in the market and 3 promising drugs in the pipeline to 2024 – see potentials of top products and promising products in development.
Review of R&D pipelines – investigate developmental trends and progress
Discussion of what stimulates and restrains companies in the market
Prospects for established firms and those seeking to enter the market
View opinions from our survey, seeing interviews with three leading authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Alzheimer’s disease therapeutics and diagnostics market and leading companies. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Report Overview
1.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market Overview
1.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Alzheimer’s Disease: An Introduction
2.1 Neurodegenerative Diseases
2.1.1 What is Alzheimer’s Disease?
2.1.2 What Causes Alzheimer’s Disease?
2.1.2.1 Alzheimer’s Disease: Type 3 Diabetes?
2.1.3 Management of Alzheimer’s Disease
2.1.4 The Socio-Economic Impact of Alzheimer’s Disease
2.1.5 Diagnosis of Alzheimer’s Disease

3. Alzheimer’s Disease Therapeutics and Diagnostics Market 2014-2024
3.1 Alzheimer’s Disease Therapeutics and Diagnostics Market, 2013
3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
3.2.2 Healthcare Costs for Alzheimer’s Disease Will Surpass All Other Medical Expenses
3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
3.3 Drivers and Restraints

4. The Alzheimer’s Disease Drugs Market, 2014-2024
4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer’s disease
4.2 The Alzheimer’s Disease Drugs Market, 2013
4.3 Changing Market Shares of the Leading Alzheimer’s Disease Drugs, 2014-2024
4.4 The Alzheimer’s Disease Drugs Market Forecast 2014-2024
4.5 Namenda
4.5.1 Namenda Sales Forecast, 2014-2024
4.6 Aricept
4.6.1 Aricept Sales Forecast, 2014-2024
4.7 Exelon
4.7.1 Exelon Sales Forecast, 2014-2024
4.8 Alzheimer’s Disease Drugs Pipeline, 2014
4.8.1 Recent High-Profile Failures of Clinical Trials for Alzheimer’s Disease Drug Candidates
4.8.1.1 Solanezumab (Eli Lilly)
4.8.1.2 LY-2886721 (Eli Lilly)
4.8.1.3 GSK2647544 (GSK)
4.8.1.4 Bapineuzumab (Elan/J&J/Pfizer)
4.8.1.5 Gammagard (Baxter)
4.9 FDA to Relax Rules for the Approval of Alzheimer’s Drugs
4.10 Will Novel Drug Development Strategies Prove Successful?
4.11 Promising Therapies in the Alzheimer’s Disease Drugs Pipeline, 2013
4.11.1 Solanezumab (Eli Lilly)
4.11.1.1Solanezumab Sales Forecast 2014-2024
4.11.2 Gantenerumab (Roche)
4.11.2.1The Gantenerumab Pipeline Forecast, 2014-2024
4.11.3 MK-8931 (Merck)
4.11.3.1 The MK-8931 Pipeline Forecast, 2014-2024
4.11.4 TTP488 (TransTechPharma)
4.11.5 LMTX (TauRx)
4.11.6 EVP-6124 (Forum Pharmaceuticals)
4.12 Deep Brain Stimulation (Functional Neuromodulation)
4.13 Leading Companies in the Alzheimer’s Disease Drugs Market, 2013
4.13.1 Pfizer, Inc
4.13.1.1Sales and Recent Performance Analysis, 2013
4.13.1.2 Pfizer: Aricept
4.13.1.3 Pfizer: R&D Capabilities and Alzheimer’s Disease Drug Candidates
4.13.2 Eisai
4.13.2.1 Sales and Recent Performance Analysis, 2013
4.13.2.2 Eisai: Aricept
4.13.2.3 Eisai: R&D Capabilities and Alzheimer’s Disease Drug Candidates
4.13.2.4 Collaboration with Biogen
4.13.2.5 Partnership with GE Healthcare for Diagnostic Development
4.13.3 Forest Laboratories (Acquired by Actavis)
4.13.3.1Acquisition by Actavis
4.13.3.2 Forest: Namenda
4.13.3.3 Namenda’s Sales and Recent Performance Analysis, 2013
4.13.4 Lundbeck A/S
4.13.4.1 Sales and Recent Performance Analysis, 2013
4.13.4.2 Lundbeck: R&D Capabilities
4.13.4.3 Lundbeck’s Alzheimer’s Disease Drug Pipeline
4.13.4.4 Lundbeck: Ebixa
4.13.5 Daiichi Sankyo
4.13.5.1 Financial Sales and Recent Performance, 2013
4.13.5.2 Daiichi Sankyo: Memary
4.13.6 Novartis AG
4.13.6.1 Sales and Recent Performance Analysis, 2013
4.13.6.2 Novartis: Exelon
4.13.6.3 eHealth Programme Delivering Innovation
4.13.6.4 Novartis: Alzheimer’s Disease Drug Pipeline
4.13.7 TauRx
4.13.7.1 Partnership with Bayer Schering Pharma AG
4.13.8Transtech Pharma
4.13.8.1TTP Translational Technology
4.13.8.2 TranstechPharma: Alzheimer’s Disease Pipeline Portfolio

5. The Alzheimer’s Disease Diagnostics Market, 2014-2024
5.1 There is Still a Strong Market Need for Effective Diagnosis
5.2 The Alzheimer’s Disease Diagnostics Market, 2013
5.3 Changing Market Shares of Leading Alzheimer’s Diagnostic Markets, 2014-2024
5.4 The Alzheimer’s Diagnostics Market, 2014-2024
5.5 New Criteria and Guidelines to Diagnose Alzheimer’s Disease
5.6 Biomarkers for Alzheimer’s Disease
5.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies
5.7 Alzheimer’s Disease: Advances in Diagnostic Imaging Technologies
5.7.1 Structural Imaging
5.7.2 Functional Imaging
5.7.3 Molecular Imaging Technologies
5.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)
5.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)
5.7.3.3 Flutemetamol (GE Healthcare)
5.7.3.4 Florbetaben (Piramal Imaging)
5.8 Other Alzheimer’s Diagnostics in Development
5.8.1 CSF Proteins
5.8.2 Blood Based Biomarkers for Alzheimer’s Disease
5.8.3 Genetic Risk Profiling
5.8.4 Eye Tests
5.9 Leading Companies in the Alzheimer’s Disease Diagnostics Market, 2014
5.9.1 Eli Lilly
5.9.1.1 Recent Performance and Sales Analysis, 2013
5.9.1.2 Alzheimer’s Disease Research Effort
5.9.1.3 Solanezumab
5.9.1.4 Amyvid (Florbetapir F18)
5.9.1.5 Amyvid Receives Marketing Authorization from the European Commission
5.9.1.6 LY-2886721: Terminated Drug
5.9.1.7 N3pG-AB mAb:Phase I
5.9.1.8 Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme
5.9.2 Amarantus BioScience Holdings, Inc.
5.9.2.1 Recent Performance and Sales Analysis, 2013
5.9.2.2 LymPro
5.9.2.3 Intellectual Property Acquisitions
5.9.3 Piramal Enterprises
5.9.3.1Piramal Imaging SA
5.9.3.2 U.S. and EMA Approval of Florbetaben
5.9.3.3 Manufacturing and Distribution Agreements
5.9.4 GE Healthcare
5.9.4.1 GE’s Commitment to Imaging Research in the Alzheimer’s Field
5.9.4.2 Regulatory Approval of Flutemetamol
5.9.4.3 Licensing Agreements for Flutemetamol
5.9.5 Navidea
5.9.5.1 NAV4694 (Fluorine-18)
5.9.5.2 Collaboration Agreements
5.9.5.3 NAV4694 Clinical Development
5.9.6 Diagenic
5.9.6.1 Organisational Restructuring

6. The Leading National Markets, 2014-2024
6.1 Regional Breakdown of the Global Alzheimer’s Disease Therapeutics and Diagnostic Market, 2013
6.1.1 The US and Europe Represent More than 70% of the Total Market
6.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Regional Forecast, 2014-2024
6.3 Changing Market Shares of Leading National Markets 2014-2024
6.4 The US Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
6.4.1 One in Eight Over the Age of 65 has AD in the US
6.4.2 The US Will Remain the Largest Market Over the Forecast Period
6.5 The European Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
6.5.1 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.5.2 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast,
2014-2024
6.5.3 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-
2024
6.5.4 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, #
2014-2024
6.5.5 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast,
2014-2024
6.5.6 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market
Forecast, 2014-2024
6.6 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.7 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.8 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.9 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.10 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.11 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024

7. Qualitative Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
7.1 SWOT Analysis
7.2 Strengths
7.2.1 Alzheimer’s Disease is a High Profile Disease
7.2.2 Expanding Patient Population
7.2.3 Strong R&D Pipeline in Both Sectors of the Market
7.3 Weaknesses
7.3.1 Current Drugs Only Treat the Symptoms of Alzheimer’s Disease
7.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
7.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
7.4. Opportunities
7.4.1 Regulations Seeking Improved Standards of Alzheimer’s Disease Drug Development
7.4.2 Neurodegenerative Diseases Have Strong R&D
7.4.3 Emerging Markets Will Help Drive the Market
7.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
7.5 Threats
7.5.1 Patent Expiries Will Lead to Further Generic Competition
7.5.2 New AD Therapies Face Political, Commercial and Social Pressures
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors
7.6.2 Threats of New Entrants
7.6.3 Powers of Suppliers
7.6.4 Bargaining Power of Buyers
7.6.5 Threat of Substitutes

8. Expert Opinions
8.1 Dr Simon Ridley, Head of Research, Alzheimer’s Research UK
8.1.1 Alzheimer’s Treatment in Late Stage Development
8.1.2 The Benefits of Alzheimer’s Diagnosis: A Future Prospect
8.1.3 Alzheimer’s and its Relationship with Other Diseases
8.1.4 Strategies to Incentivise Alzheimer’s Research and Investment
8.2 David Hanlon, Director of Business Development and Strategic Collaborations, Quanterix
8.2.1 Ultra Sensitive Automated Immunoassay Platform for Alzheimer’s
8.2.2 Alzheimer’s Disease Blood-based Biomarkers
8.2.3 Research Based Setting of the Simoa Technology
8.2.4 Quanterix: Alzheimer’s Partners and Collaborations
8.3 Elizabeth Edgerly, Ph.D., Chief Program Officer, The Alzheimer’s Association Northern California and Northern Nevada
8.3.1 Alzheimer’s Severe Under diagnosis
8.3.2 Novel Biomarkers: Critical for Alzheimer’s Diagnosis
8.3.3 Alzheimer’s Treatment Paradigm: Needs to be More Universally Effective
8.3.4 A Push to Improve the Success of Alzheimer’s Research
8.3.5 Alzheimer’s Treatment: The Greatest Challenge

9. Conclusions
9.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
9.2 Disease Modifying Drugs Will Transform the Declining Alzheimer’s Market
9.3 Demographics Will Help Drive the Market Over the Forecast Period
9.4 Medicines and Diagnostic Tests for Alzheimer’s Disease Hold Great Potential from 2014 to 2024

List of Tables
Table 2.1 Leading Sectors in the Neurodegenerative Disease Market, 2014
Table 2.2 Imaging Technologies Used in Alzheimer’s Research, 2014
Table 3.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Shares (%) by Sector, 2013
Table 3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.1 The Alzheimer’s Disease Drugs Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2013
Table 4.2 Market Shares (%) of the Leading Alzheimer’s Drugs, 2013, 2018, 2024
Table 4.3 The Alzheimer’s Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.4 Namenda: Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.5 Aricept: Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.6 Exelon: Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.7 Selected List of Alzheimer’s Disease Drugs in the Pipeline, 2014
Table 4.8 Eli Lilly: Solanezumab Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.9 Roche: Gantenerumab Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.10 Merck: MK-8931 Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.11 Pfizer: Revenues ($bn) and Revenue Shares (%) by Sector, 2013
Table 4.12 Pfizer: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.13 Pfizer: Alzheimer’s Disease Drug Pipeline, 2014
Table 4.14 Eisai: Aricept Regional Sales ($m), AGR (%), 2013
Table 4.15 Eisai: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.16 Biogen: Alzheimer’s Disease Drugs Pipeline, 2014
Table 4.17 Forest: Namenda’s Historical Revenues ($bn), AGR (%) and Percentage of Net Sales (%), 2009-2014
Table 4.18 Forest: Namenda Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.19 Lundbeck: Revenue ($bn) and Revenue Share (%) by Region, 2013
Table 4.20 Ebixa: Revenue ($bn) and Revenue Share (%) by Region, 2013
Table 4.21 Ebixa: Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.22 Daiichi Sankyo: Memary Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.23 Novartis: Revenue ($bn) and Revenue Shares (%) by Segment, 2013
Table 4.24 Transtech Pharma: Alzheimer’s Disease Drugs Pipeline, 2014
Table 5.1 The Alzheimer’s Disease Diagnostics Market: Revenues ($bn) and Market Shares (%) by Segment, 2013
Table 5.2 Market Shares (%) of the Leading Alzheimer’s Diagnostics Markets, 2013, 2018 and 2024
Table 5.3 The Alzheimer’s Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%),
CAGR (%) by Segment, 2013-2024
Table 5.4 Key Alzheimer’s Diagnostic Tests in Development, 2014
Table 5.5 Diagenic: Alzheimer’s Disease Diagnostics Pipeline and Current Developments, 2014
Table 6.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Share (%) by Region, 2013
Table 6.2 The Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%) by Region, 2013-2024
Table 6.3 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast CAGR (%), 2013-2018, 2018-2024, 2013-2024
Table 6.4 Market Shares (%) of the Leading Regional Alzheimer’s Disease Therapeutics and Diagnostics Markets, 2013, 2018 and 2024
Table 6.5 The US Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.6 The European Alzheimer’s Therapeutics and Diagnostics Market: Revenue ($bn),
European Market Share (%) and Global Market Share (%) by Leading Countries, 2013
Table 6.7 The European Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.8 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.9 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.10 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.11 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.12 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.13 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market
Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.14 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.15 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.16 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.17 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.18 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 6.19 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market
Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Table 7.1SWOT Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014
Table 9.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2013, 2018 and 2024 and CAGR (%, 2013-2018 and 2018-2024) by Region
Table 9.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market ($bn) by Sector, 2013, 2018 and 2024

List of Figures
Figure 1.1 The Global Over 65 Population: Forecast (millions, AGR%), 2013-2024
Figure 1.2 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 1.3 Alzheimer’s Disease Therapeutics and Diagnostics: Overview of Submarkets and Segments
Figure 3.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Sector, 2013
Figure 3.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Market Share (%) by Sector, 2013
Figure 3.3 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 4.1 The Alzheimer’s Disease Drugs Market: Revenues ($bn) by Leading Drugs, 2013
Figure 4.2 The Alzheimer’s Disease Drugs Market: Market Shares (%) by Leading Drugs, 2013
Figure 4.3 The Alzheimer’s Therapeutics Market: Market Shares (%) by Drug, 2018
Figure 4.4 The Alzheimer’s Therapeutics Market: Market Shares (%) by Drug, 2024
Figure 4.5 The Alzheimer’s Disease Drugs Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 4.6 Namenda: Sales Forecast ($bn), AGR (%), 2013-2024
Figure 4.7 Aricept: Sales Forecast ($bn), AGR (%), 2013-2024
Figure 4.8 Exelon: Sales Forecast ($bn), AGR (%), 2013-2024
Figure 4.9 Eli Lilly: Solanezumab Sales Forecast ($bn), AGR (%), 2013-2024
Figure 4.10 Roche: Gantenerumab Sales Forecast ($bn), AGR (%), 2013-2024
Figure 4.11 Merck: MK-8931 Sales Forecast ($bn), AGR (%), 2013-2024
Figure 4.12 Pfizer: Historical Revenues ($bn), Net Income ($bn) and Profit Margin (%), 2009-2013
Figure 4.13 Pfizer: Revenues ($bn) by Sector, 2013
Figure 4.14 Pfizer: Revenue Shares (%) by Sector, 2013
Figure 4.15 Pfizer: Aricept Historical Revenues ($bn) and AGR(%), 2009-2013
Figure 4.16 Pfizer: Aricept Sales Forecast ($bn), AGR (%), 2013-2024
Figure 4.17 Pfizer: Historical R&D Expenditure ($bn) and R&D Expenditure as Percentage of Revenue (%), 2011-2013
Figure 4.18 Eisai: Aricept Sales Forecast ($bn), AGR (%), 2013-2024
Figure 4.19 Eisai: Historical R&D Expenditure ($bn) and R&D Expenditure as Percentage of Revenue (%), 2012-2013
Figure 4.20 Forest: Namenda’s Historical Revenue ($bn), AGR (%), 2009-2014
Figure 4.21 Forest: Namenda Sales Forecast ($bn), AGR (%), 2013-2024
Figure 4.22 Lundbeck: Revenue Share (%) by Region, 2013
Figure 4.23 Lundbeck: Revenue Share ($bn) by Region, 2013
Figure 4.24 Lundbeck: Historical R&D Expenditure ($bn) and R&D Expenditure as Percentage of Revenue (%), 2011-2013
Figure 4.25 Ebixa: Revenue Shares (%) by Region, 2013
Figure 4.26 Ebixa: Sales Forecast ($bn), AGR (%), CAGR (%), 2013-2024
Figure 4.27 Daiichi Sankyo: Historical Revenue ($bn), Net Income ($bn) and Profit Margin (%), 2010-2013
Figure 4.28 Daiichi Sankyo: Memary Historical Revenue ($bn), 2012-2013
Figure 4.29 Daiichi Sankyo: Memary Sales Forecast ($bn), AGR (%), 2013-2024
Figure 4.30 Novartis: Historical Revenues ($bn), Net Income ($bn) and Profit Margin (%), 2010-2013
Figure 4.31 Novartis: Revenues ($bn) by Segment, 2013
Figure 4.32 Novartis: Revenue Shares(%) by Segment, 2013
Figure 4.33 Exelon: Revenue Shares (%) by Region, 2013
Figure 5.1 The Alzheimer’s Disease Diagnostics Market: Revenues ($bn) by Segment, 2013
Figure 5.2 The Alzheimer’s Disease Diagnostics Market: Market Shares (%) by Segment, 2013
Figure 5.3 The Alzheimer’s Diagnostics Market: Market Share (%) by Segment, 2018
Figure 5.4 The Alzheimer’s Diagnostics Market: Market Share (%) by Segment, 2024
Figure 5.5 The Alzheimer’s Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%), 2013-2024
Figure 5.6 Eli Lilly: Historical Revenue ($bn), Net Income ($bn), Profit Margin (%), 2011-2013
Figure 5.7 AmarantusBioScience: R&D Costs ($m), 2012-2013
Figure 6.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Region, 2013
Figure 6.2 The Alzheimer’s Disease Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2013
Figure 6.3 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2013-2018
Figure 6.4 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2018-2024
Figure 6.5 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2013-2024
Figure 6.6 The Alzheimer’s Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2018
Figure 6.7 The Alzheimer’s Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2024
Figure 6.8 The US Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2013-2024
Figure 6.9 The US Demographics: No. of People Aged 65 or Over, 2013 and 2025 Forecast
Figure 6.10 The European Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Leading Countries, 2013
Figure 6.11 The European Alzheimer’s Disease Therapeutics and Diagnostics Market : Market Shares (%) by Leading Countries, 2013
Figure 6.12 The European Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 6.13 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 6.14 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 6.15 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 6.16 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 6.17 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%),2013-2024
Figure 6.18 The Other European Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 6.19 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 6.20 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 6.21 China’s Historical Healthcare Expenditure ($bn), 2001-2010
Figure 6.22 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 6.23 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($m), AGR (%),2013-2024
Figure 6.24 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 6.25 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%),2013-2024
Figure 7.1 Porter’s Five Force Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014
Figure 9.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2013, 2018 and 2024
Figure 9.2 The Global Alzheimer’s Disease Therapeutics and diagnostics Market ($bn) by
Segment, 2013, 2018 and 2024

Companies Listed

AbbVie
AC Immune
Acadia Pharmaceuticals
Accera
Actavis
Adamas Pharmceuticals
Affiris
Amarantus BioSciences
Amorphis
Archer Pharmaceuticals
Astex
AstraZeneca
Avanir Pharmaceuticals
Avineuro Pharmaceuticals
Baxter
Bayer
Bayer Schering Pharma
Biogen
bioMerieux
Ceregene
Chiesi Farmaceutici
Cognoptix
Cytos
Daiichi Sankyo
DiaGenic
Eisai
Elan
Eli Lilly
EnVivo Pharmaceuticals
Forest Laboratories
Forum Pharmaceuticals
Foundation Medical Partners
Functional Neuromodulation
GE Healthcare
General Electric
Genervon Biopharmaceuticals
Genesys Capital
GSK
Hisamitsu Pharmaceutical
Humanetics
IBA Molecular
J&J
Janssen Alzheimer Immunotherapy Research & Development
Janssen Pharmaceutical K. K
Kareus Therapeutics
LabCorp
Luminex
Lundbeck
Medtronic
Merck & Co
Merz
Meso Scale Diagnostics
Metabolic Solutions Development Company
MorphoSys
Nanotherapeutics
Navidea
NextGen Sciences
Novartis
Novo Nordisk
Ono Pharmaceutical
OPKO
Ortho Clinical Diagnostics
Otsuka Pharmaceutical
Oxford BioDynamics
Par Pharmaceuticals
Pfizer
Piramal Enterprises
Piramal Imaging
Proteome Sciences
ProteoTech
Proterra
QR Pharma
Quanterix
Raptor Pharmaceutical
Resverlogix
Roche
Roche Diagnostics
Saladax
Sangamo BioSciences
Sanofi
sGC Pharma
Shionogi
Shire
Siemens Medical Solutions USA
Somalogic
Sonexa Therapeutics
Sun Pharma
T3D Therapeutics
Takeda
Targacept
TauRx
Toyama Chemical
Transition Therapeutics
TransTech Pharma
United Biomedical
VIVUS
Wyeth

Other Organisations Mentioned in This Report
Alzheimer’s Association International Conference (AAIC)
Alzheimer’s Research UK
Assogenerici (Italy)
Cambridge University
Cleveland Clinic Lou Ruvo Center for Brain Health
Dementia UK
French Economic Committee
King’s College London
Ministry of Health, Labout and Welfare (MHLW) (Japan)
National Health Services (Italy)
National Health Services (NHS) (UK)
National Institute of Clinical Excellence (NICE)
National Institute of Health (NIH)
The Alzheimer’s Association
The Centers for Medicare and Medicaid Services (CMS)
The Central Drug Standard Control Organisation (CDSCO)
The Duke University
The European Commission
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)
The Food and Drug Administration FDA (US)
The Health and Social Care Information Centre
The National Institute of Aging (NIA)
The Supreme Court of Japan
The University of Aberdeen
The University of Cologne
The University of Pittsburgh
Trinity College Dublin
United Nations (UN)
World Health Organisation (WHO)

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close